Scarica l'app Stockscreener
297.89
1.63%
4.77
Dopo l'orario di chiusura:
297.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$293.12
Aprire:
$293.99
Volume 24 ore:
372.40K
Relative Volume:
0.72
Capitalizzazione di mercato:
$13.44B
Reddito:
$2.99B
Utile/perdita netta:
$1.21B
Rapporto P/E:
11.89
EPS:
25.06
Flusso di cassa netto:
$1.13B
1 W Prestazione:
+1.59%
1M Prestazione:
+2.46%
6M Prestazione:
-19.77%
1 anno Prestazione:
-10.44%
Intervallo 1D:
$293.99
$298.91
Intervallo di 1 settimana:
$290.80
$302.52
Portata 52W:
$266.98
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Confronta UTHR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag - Insider Monkey
What analysts say about United Therapeutics Corporation stockConsistent triple returns - jammulinksnews.com
Is United Therapeutics Corporation a good long term investmentBreakthrough profit margins - jammulinksnews.com
United Therapeutics Corporation Stock Analysis and ForecastAccelerated profit realization - jammulinksnews.com
What drives United Therapeutics Corporation stock priceSkyrocketing investment returns - jammulinksnews.com
Morgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating - Insider Monkey
Here's Why United Therapeutics (UTHR) is a Strong Value Stock - Yahoo Finance
Pulmonary Arterial Hypertension Market Forecast 2034: - openPR.com
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Pulmonary Arterial Hypertension Drug Market Forecast to 2032: - openPR.com
United Therapeutics Announces Q2 Earnings Date: Key Details for Biotech Investment Community - Stock Titan
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest - Yahoo Finance
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $510 - 富途牛牛
Reflecting On Therapeutics Stocks' Q1 Earnings: Moderna (NASDAQ:MRNA) - FinancialContent
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA) - Yahoo Finance
United Therapeutics Puts Big Bets On Tyvaso’s Trial Results - Finimize
United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says - MarketScreener
United Therapeutics (UTHR) Awaits Key Catalyst with Positive Ris - GuruFocus
United Therapeutic's: The Brands First Hydrogen Helicopter - Energy Digital Magazine
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors - TipRanks
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - Insider Monkey
United Therapeutics (UTHR) Price Target Adjustment by Morgan Sta - GuruFocus
United Therapeutics (UTHR) Price Target Trimmed by Morgan Stanle - GuruFocus
United Therapeutics' Inhaled Treprostinil Study for Pulmonary Fibrosis: Key Insights for Investors - AInvest
United Therapeutics (UTHR): JP Morgan Adjusts Price Target | UTH - GuruFocus
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lowered by UBS | UTHR Stock News - GuruFocus
United Therapeutics’ Promising Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lo - GuruFocus
United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study - Yahoo Finance
United Therapeutics EVP Mahon sells $3.14 million in UTHR stock - Investing.com
United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment - TipRanks
5 Must-Read Analyst Questions From United Therapeutics’s Q1 Earnings Call - Yahoo Finance
United Therapeutics (UTHR) Begins Groundbreaking Clinical Study with miroliverELAP | UTHR Stock News - GuruFocus
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? - Yahoo Finance
United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus
United Therapeutics: Tanking On Rival's PAH DataI'd Consider Buying Stock (NASDAQ:UTHR) - Seeking Alpha
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com
United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News
Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset - Seeking Alpha
Treprostinil Saga Continues - JD Supra
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.70%
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):